MoonLake Immunotherapeutics - Class A — Quarterly Cash Flow (NASDAQ:MLTX) | MetaTrader

Open full chart

Financials

Overview 明細書 Statistics Dividends

Quarterly Annual

Total assets 518.21 M477.93 M511.26 M460.1 M414.33 M424.43 M Total liabilities 22.71 M24.54 M98.68 M102.15 M123.14 M119.95 M Total equity 495.5 M453.39 M412.58 M357.94 M291.19 M304.48 M Total liabilities & shareholders' equities 518.21 M477.93 M511.26 M460.1 M414.33 M424.43 M Total debt —————— Net debt ——————

ニュース

MoonLake: Downgrade To Buy As Sonelokimab Still Has A BLA Shot On Goal (NASDAQ:MLTX)

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day - Slideshow (NASDAQ:MLTX) 2026-02-23

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript

MoonLake株、軸性脊椎関節炎試験の良好なデータで急騰

MoonLake stock surges on positive axSpA trial data

InvestingProの適正価値判定後、MoonLake株が63%急騰

MoonLake stock surges 63% after InvestingPro Fair Value call

MoonLake、軸性脊椎関節炎のフェーズ2で良好なデータを報告

MoonLake reports positive phase 2 axial spondyloarthritis data

ImageneBio appoints Dr. Porter-Brown as Chief Medical Officer

BTIGがデータ発表を前にムーンレイク・イムノセラピューティクス株の買い推奨を再確認

BTIG reiterates Buy rating on Moonlake Immunotherapeutics stock ahead of data